All Stories

  1. HbA1c and leukocyte mtDNA levels as major factors associated with post-COVID-19 syndrome in type 2 diabetes patients
  2. Gut Microbiota, Deranged Immunity, and Hepatocellular Carcinoma
  3. Corrigendum to: ’Protective effect of vaginal resveratrol administration on joint tissues in ovariectomized rats: Targeting mTOR and сaspase 3’ [Biomed. Pharmacother. (2023) 115176/165]
  4. Gender Differences in Patients with Prolactinoma: Single-center Ukrainian Experience
  5. Association between intestinal microflora and obesity
  6. Digital pathology implementation in cancer diagnostics: towards informed decision-making
  7. Microbiota substances modulate dendritic cells activity: A critical view
  8. Probiotic co-supplementation with absorbent smectite for pancreatic beta-cell function in type 2 diabetes: a secondary-data analysis of a randomized double-blind controlled trials
  9. Prognostic factors for surgical treatment of prolactin-secreting pituitary adenomas
  10. Ethical navigation of biobanking establishment in Ukraine: learning from the experience of developing countries
  11. Accuracy of attenuation coefficient measurement (ACM) for real-time ultrasound hepatic steatometry: Comparison of simulator/phantom data with magnetic resonance imaging proton density fat fraction (MRI-PDFF)
  12. Probiotic for Pancreatic β-Cell Function in Type 2 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial
  13. Probiotics for pancreatic β-cell function: from possible mechanism of action to assessment of effectiveness
  14. Protective effect of vaginal resveratrol administration on joint tissues in ovariectomized rats: Targeting mTOR and сaspase 3
  15. Antimicrobial activity of dietary supplements based on bacterial lysate of Lactobacillus rhamnosus DV
  16. The detrimental consequences of two consecutive disasters impacting cytopathology in Ukraine: COVID followed by the war
  17. Gut microbiota in patients with COVID-19 and type 2 diabetes: A culture-based method
  18. Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis
  19. Efficacy and safety of fecal microbiota transplantation via colonoscopy as add-on therapy in patients with mild-to-moderate ulcerative colitis: A randomized clinical trial
  20. Fecal Microbiota Transplantation in Diseases Not Associated with Clostridium difficile: Current Status and Future Therapeutic Option
  21. Microbiome and Obesity
  22. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
  23. Changes in Metabolic Parameters in Patients with Diabetic Kidney Disease Depending on the Status of D3
  24. Fecal microbiota transplantation in patients with post-infectious irritable bowel syndrome: A randomized, clinical trial
  25. Resveratrol Effects on the Reproductive System in Ovariectomized Rats: Deciphering Possible Mechanisms
  26. Nutrition program, physical activity and gut microbiota modulation: a randomized controlled trial to promote a healthy lifestyle in students with vitamin D3 deficiency
  27. Precision oncology: ethical challenges and justification
  28. Akkermansia muciniphila as a novel powerful bacterial player in the treatment of metabolic disorders
  29. Response to neoadjuvant chemotherapy in breast cancer: do microRNAs matter?
  30. Immune Microenvironment of Muscular-Invasive Urothelial Carcinoma: The Link to Tumor Immune Cycle and Prognosis
  31. Global multi-stakeholder endorsement of the MAFLD definition
  32. Effect of a specific Escherichia coli Nissle 1917 strain on minimal/mild hepatic encephalopathy treatment
  33. Correction of Androgen Deficiency in Men with Type 2 Diabetes
  34. Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation
  35. Gut Microbiota Interactions With Obesity
  36. SEMI-QUANTITATIVE EVALUATION OF THE HEPATIC AND PANCREATIC STEATOSIS BY GRAY SCALE ECHOGENICITY
  37. STRATIFICATION OF LIVER STEATOSIS BY THE ATTENUATION COEFFICIENT MEASUREMENT (ACM) OF THE HAND-HELD ULTRASOUND DEVICE
  38. Probiotics and obesity associated disease: an extended view beyond traditional strains
  39. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
  40. Histological differentiation impacts the tumor immune microenvironment in gastric carcinoma: Relation to the immune cycle
  41. Alleviation of halitosis by use of probiotics and their protective mechanisms in the oral cavity
  42. Immunomodulatory role of Faecalibacterium prausnitzii in obesity and metabolic disorders
  43. Microbial and immune markers of patients with metabolic syndrome and cardiovascular diseases: perspectives for early diagnostics
  44. Vitamin D in the prevention and treatment of type-2 diabetes and associated diseases: a critical view during COVID-19 time
  45. Metabolic Benefits of Probiotic Combination with Absorbent Smectite in type 2 Diabetes Patients a Randomised Controlled Trial
  46. Probiotic Composition and Chondroitin Sulfate Regulate TLR-2/4-Mediated NF-κB Inflammatory Pathway and Cartilage Metabolism in Experimental Osteoarthritis
  47. Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial
  48. Next generation of strain specific probiotics in diabetes treatment: the case of Prevotella copri
  49. Hepatic steatosis indices as predictors of vitamin D3 deficiency in patients with NAFLD associated with type 2 diabetes
  50. Dietary pattern, colonic microbiota and immunometabolism interaction: new frontiers for diabetes mellitus and related disorders
  51. Probiotic and omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance, improves glycemia and obesity parameters in individuals with type 2 diabetes: A randomised controlled trial
  52. Vitamin D3 deficiency is associated with more severe insulin resistance and metformin use in patients with type 2 diabetes
  53. Probiotics function and modulation of the immune system in allergic diseases
  54. Mechanisms of the Impact of Hashimoto Thyroiditis on Papillary Thyroid Carcinoma Progression: Relationship with the Tumor Immune Microenvironment
  55. Combined effects of probiotic and chondroprotector during osteoarthritis in rats
  56. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
  57. Crosstalk between gut microbiota and osteoarthritis: A critical view
  58. Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo‐controlled CARMELINA® trial
  59. New insights on strain-specific impacts of probiotics on insulin resistance: evidence from animal study
  60. Importance of the Microbiota Inhibitory Mechanism on the Warburg Effect in Colorectal Cancer Cells
  61. Probiotics and smectite absorbent gel formulation reduce liver stiffness, transaminase and cytokine levels in NAFLD associated with type 2 diabetes: a randomized clinical study
  62. Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial
  63. Effect of probiotic on serum cytokines and matrix metalloproteinases profiles during monoiodoacetate-induced osteoarthritis in rats
  64. Crosstalk between gut microbiota and antidiabetic drug action
  65. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
  66. Neuropathic diabetic foot ulcers treated with cerium dioxide nanoparticles: A case report
  67. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
  68. Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study
  69. Polyphenol Compounds Melanin Prevented Hepatic Inflammation in Rats with Experimental Obesity
  70. Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
  71. Wpływ Z56822977 na biosyntezę serotoniny w mózgu szczurów z otyłością wywołaną przez podawanie glutaminianu sodu
  72. The correction of the metabolic parameters of msg-induced obesity in rats by 2-[4-(benzyloxy) phenoxy] acetic acid
  73. Probiotics and nutraceuticals as a new frontier in obesity prevention and management
  74. Effect of alive probiotic on insulin resistance in type 2 diabetes patients: Randomized clinical trial
  75. The role of nanotechnology in food safety
  76. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high ca...
  77. A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial
  78. Efficacy of Probiotics and Smectite in Rats with Non-Alcoholic Fatty Liver Disease
  79. Immunomodulatory effects of stem cells: Therapeutic option for neurodegenerative disorders
  80. Cerium dioxide nanoparticles possess anti-inflammatory properties in the conditions of the obesity-associated NAFLD in rats
  81. H 2 S causes contraction and relaxation of major arteries of the rabbit
  82. Effects of polyphenol compounds melanin on NAFLD/NASH prevention
  83. The Impact of Hyperglycemia on VEGF Secretion in Retinal Endothelial Cells
  84. Attenuation coefficient measurement as novel real time ultrasound alternative to CAP (fibroscan)
  85. Effect of a probiotic on fatty liver index and liver stiffness in NAFLD patients: randomized clinical trial
  86. Nanocrystalline cerium dioxide efficacy for prophylaxis of erosive and ulcerative lesions in the gastric mucosa of rats induced by stress
  87. Perspectives and challenges of antioxidant therapy for atrial fibrillation
  88. Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer
  89. Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity
  90. The Role of Liver Biopsy to Assess Alcoholic Liver Disease
  91. Prevention of NAFLD development in rats with obesity via the improvement of pro/antioxidant state by cerium dioxide nanoparticles
  92. Comparative experimental investigation on the efficacy of mono- and multiprobiotic strains in non-alcoholic fatty liver disease prevention
  93. Caffeine and cardiovascular diseases: critical review of current research
  94. Probiotics in prevention and treatment of obesity: a critical view
  95. Pathophysiological role of host microbiota in the development of obesity
  96. Probiotics for experimental obesity prevention: focus on strain dependence and viability of composition
  97. Antioxidative effects of cerium dioxide nanoparticles ameliorate age-related male infertility: optimistic results in rats and the review of clinical clues for integrative concept of men health and fertility
  98. Diagnostic accuracy of acyl-ghrelin and it association with non-alcoholic fatty liver disease in type 2 diabetic patients
  99. P0968 : Are the type of probiotic strains and their amount equally effective for NAFLD prevention? Experimental comparative study
  100. Diagnosis of experimental stetohepatosis using ultrasound shear wave elastography
  101. The Role of Liver Biopsy to Assess Non-Alcoholic Fatty Liver Disease
  102. Multiprobiotic therapy from childhood prevents the development of nonalcoholic fatty liver disease in adult monosodium glutamate-induced obese rats
  103. P269 SHORT-TERM PERIODIC ADMINISTRATION OF MULTIPROBIOTIC FROM CHILDHOOD PREVENTS DEVELOPMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN ADULT MONOSODIUM GLUTAMATE-INDUCED OBESE RATS
  104. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3
  105. Short-term periodic consumption of multiprobiotic from childhood improves insulin sensitivity, prevents development of non-alcoholic fatty liver disease and adiposity in adult rats with glutamate-induced obesity
  106. Metabolic profile and morpho-functional state of the liver in rats with glutamate-induced obesity
  107. 1329 DIAGNOSTIC ACCURACY OF A NEW ELASTOGRAPHIC METHOD (SHEAR WAVE™ ELASTOGRAPHY IMAGING) IN THE NONINVASIVE ASSESSMENT OF NON-ALCOHOLIC STEATOSIS IN PATIENTS WITH TYPE 2 DIABETES
  108. 1267 PERFORMANCE OF NEW ULTRASOUND METHOD FOR ASSESSING LIVER STIFFNESS – SHEAR WAVE™ ELASTOGRAPHY IMAGING IN RATS WITH EXPERIMENTAL OBESITY